[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-333968-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-333968-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","genetic-associations-of-visfatin-polymorphisms-with-clinicopathologic-characteristics-of-prostate-cancer-in-taiwanese-males","Genetic associations of visfatin polymorphisms with clinicopathologic characteristics of prostate cancer in Taiwanese males","","Prostate cancer is the most common malignancy in men and its risk increases with age and obesity. Visfatin, an adipokine implicated in cancer progression and metastasis, has an unclear relationship to prostate cancer. This study evaluated four visfatin gene polymorphisms and clinicopathological characteristics in 695 Taiwanese males with prostate cancer. Carriers of the GA+AA heterozygote of rs61330082 showed a markedly higher risk of biochemical recurrence than GG carriers. Visfatin rs61330082 and rs11977021 were associated with higher perineural invasion, lymphovascular invasion, and biochemical recurrence in PSA > 10 patients.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/genetic-associations-of-visfatin-polymorphisms-with-clinicopathologic-characteristics-of-prostate-cancer-in-taiwanese-males/333968/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/genetic-associations-of-visfatin-polymorphisms-with-clinicopathologic-characteristics-of-prostate-cancer-in-taiwanese-males/333968.png","ImageObject",300,407,{"name":42,"@type":43},"River Wang","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main objective of this study?","Question",{"text":63,"@type":64},"To investigate whether four visfatin gene polymorphisms are associated with clinicopathological characteristics and the risk of developing prostate cancer in Taiwanese males.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which visfatin polymorphism was linked to a higher risk of biochemical recurrence?",{"text":68,"@type":64},"Carriers of the GA+AA heterozygote of SNP rs61330082 had a significantly higher risk of biochemical recurrence than those with the GG genotype.",{"name":70,"@type":61,"acceptedAnswer":71},"Did visfatin mRNA levels relate to tumor stage or survival?",{"text":72,"@type":64},"Using The Cancer Genome Atlas database, visfatin mRNA levels did not prominently differ across pathological T/N stage or overall survival.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},333968,1790197309,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":111,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":117,"preview_page_count":4},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","Ivyspring  \nInternational Publisher  \nInternationalJournal of Medical Sciences  \n2024; 21(13): 2494-2501. doi: 10.7150/ijms.101020  \nResearch Paper  \nGenetic associations of visfatin polymorphisms with clinicopathologic characteristics of prostate cancer in Taiwanese males  \nSung-Lin Hu1,2\\#, Shan-Chi Liu3\\#, Chia-Yen Lin4,5,6, Yi-Chin Fong7,8,9, Shian-Shiang Wang4,5,10, Li-Chai Chen11, Shun-Fa Yang12,13􀀍, Chih-Hsin Tang14,15,16,17􀀍  \n1. School of Medicine, China Medical University, Taichung, Taiwan.  \n2. Department of Family Medicine, China Medical University Hsinchu Hospital, Hsinchu, Taiwan.  \n3. Institute of Biomedical Sciences, Mackay Medical College, New Taipei City, Taiwan.  \n4. Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan.  \n5. School of Medicine, Chung Shan Medical University, Taichung, Taiwan.  \n6. School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.  \n7. Department of Sports Medicine, College of Health Care, China Medical University, Taichung, Taiwan.  \n8. Department of Orthopedic Surgery, China Medical University Hospital, Taichung, Taiwan.  \n9. Department of Orthopedic Surgery, China Medical University Beigang Hospital, Yunlin, Taiwan.  \n10. Department of Applied Chemistry, National Chi Nan University, Nantou, Taiwan.  \n11. Department of Pharmacy and Master Program, Collage of Pharmacy and Health Care, Tajen University, Pingtung County, Taiwan.  \n12. Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.  \n13. Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan.  \n14. Department of Pharmacology, School of Medicine, China Medical University, Taichung, Taiwan.  \n15. Department of Medical Laboratory Science and Biotechnology, Asia University, Taichung, Taiwan.  \n16. Chinese Medicine Research Center, China Medical University, Taichung, Taiwan.  \n17. Department of Medical Research, China Medical University Hsinchu Hospital, Hsinchu, Taiwan.  \n\\# These authors contributed equally.  \n􀀍 Corresponding authors: Chih-Hsin Tang, PhD (E-mail: [chtang@mail.cmu.edu.tw](chtang@mail.cmu.edu.tw)) and Shun-Fa Yang, PhD (Email: [ysf@csmu.edu.tw](ysf@csmu.edu.tw)) .  \n© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)). See [http://ivyspring.com/terms](http://ivyspring.com/terms) for full terms and conditions.  \nReceived: 2024.07.16; Accepted: 2024.09.03; Published: 2024.09.23  \nAbstract  \nThe most general cancer in men is prostate cancer (PCa), with its risk increasing due to age and obesity. Visfatin, a member of adipokines, is related to cancer progression and metastasis, but its relationship in PCa remains undetermined. In addition, no knowledge is available regarding relations between visfatin polymorphisms and clinicopathological characteristics in PCa. We sought to investigate the functions of four visfatin gene polymorphisms and clinicopathological characteristics on the hazard of developing PCain 695 Taiwanese males with PCa. Carriers of the GA+AA heterozygote of SNP rs61330082 were at a markedly higher risk of biochemical recurrence than those with the GG genotype. Visfatin rs61330082 and rs11977021 were related with a high risk of perineural invasion, lymphovascular invasion, and biochemical recurrence in prostate-specific antigen (PSA) > 10 PCa patients. The Cancer Genome Atlas database noted that visfatin mRNA level did not prominently differ with pathological T/N stage and overall survival. This finding is the first to document a connection between visfatin polymorphisms and clinicopathological characteristics of PCa in Taiwanese males.  \nKeywords: Prostate cancer; Single nucleotide polymorphism; Visfatin; Taiwanese males  \nIntroduction  \nThe most general cancer in men is prostate cancer (PCa), with its risk increasing due to age an","cbCain0N9VkU8S27","https://ap.wps.com/l/cbCain0N9VkU8S27","pdf",1253433,"English","# Abstract\n## Keywords\n## Introduction","[{\"question\":\"What was the main objective of this study?\",\"answer\":\"To investigate whether four visfatin gene polymorphisms are associated with clinicopathological characteristics and the risk of developing prostate cancer in Taiwanese males.\"},{\"question\":\"Which visfatin polymorphism was linked to a higher risk of biochemical recurrence?\",\"answer\":\"Carriers of the GA+AA heterozygote of SNP rs61330082 had a significantly higher risk of biochemical recurrence than those with the GG genotype.\"},{\"question\":\"Did visfatin mRNA levels relate to tumor stage or survival?\",\"answer\":\"Using The Cancer Genome Atlas database, visfatin mRNA levels did not prominently differ across pathological T/N stage or overall survival.\"}]","Genetic associations of visfatin polymorphisms with clinicopathologic characteristics of prostate cancer in Taiwanese males | PDF",1790004809]